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Three decades ago, near the end of a 30-hour, minimal-sleep, San Francisco–Cleveland round trip, I fell into a deep 
sleep at 36,000 feet, awakened refreshed 
somewhere over Wyoming, and was rested 
enough for once to read Nature with care. To 
my great good fortune, it was the issue that 
reported the identification of RB, the gene 
whose mutations cause the eye tumor retino-
blastoma (Friend et al., 1986). The approach 
that led to this discovery was two pronged: 
(i) searching tumor cell DNA for areas of 
recurrent loss of heterozygosity (i.e., loss of 
a  portion of one of the two copies of a chro-
mosome) that might include a putative tumor 
suppressor gene and (ii) doing family linkage 
studies on DNA gathered from kindreds with 
retinoblastomas. Because I have had a long-
term interest generally in heritable disorders 
of the skin and identification of their molec-
ular underpinnings and specifically in the 
basal cell nevus (Gorlin) syndrome (BCNS) 
(Aurbach et al., 1970), the analogy between 
the clinical findings in retinoblastoma and 
basal cell carcinomas struck me as obvious—
both came in two types: (i) the more com-
mon with a single sporadic tumor at a later 
age of onset and (ii) a rare variant, inherited 
as an autosomal dominant, often with mul-
tiple tumors and with an earlier age at onset. 
I thought that if Friend and colleagues could 
use their approach to identify the RB gene 
whose mutations underlie these tumors, we 
could use the same approach to identify the 
BCNS “gene,” and that might tell us some-
thing about the molecular aberration that 
causes the far more common sporadic basal 
cell carcinomas (BCCs). 
I immediately embarked on a project to 
gather many, many blood samples from fam-
ilies with BCNS so that we could do family 
linkage analysis and lots of BCCs so that we 
could do many, many Southern blots to iden-
tify the locus of the putative tumor suppres-
sor gene that is aberrant in BCNS patients. We 
then discovered that groups on several conti-
nents had already embarked on this quest. In 
fact, after we had struggled for several years, 
the group led by Alan Bale got there first and, 
using the same approach, localized the gene 
for which we had been searching to chromo-
some 9q (Gailani et al., 1992). The next step 
was to find the actual gene, and we and the 
rest of the community focused our efforts on 
an increasingly small area that “must” contain 
the gene. We were, as Lyndon Johnson put it, 
knee deep in the Big Muddy—lost in a forest 
with impenetrable fog that got thicker by the 
moment when, fortunately, an aha moment 
came. Matt Scott at Stanford called in October 
1995 to tell me he thought he “had” the gene 
for which we had been searching for nearly 
a decade. Matt is a superb developmental 
biologist with a long record of contributions 
to elucidating the hedgehog (HH) signaling 
pathway; he is now president of the Carnegie 
Institution for Science. His lab had cloned 
the human homolog of the Drosophila gene 
encoding ptch, the primary inhibitor of that 
pathway, and David Cox and Richard Myers, 
human geneticists at Stanford, localized it to 
9q; sure enough, there was a human disease, 
BCNS, at that site. Fortunately, he called us. 
The collaboration cleared the fog in which we 
were searching for the gene, and eight months 
later we published our findings of inactivat-
ing mutations in PTCH1 in BCNS patients and 
in DNA from sporadic and inherited BCCs 
(Johnson et al., 1996). Oh yes, on the very 
same day in June 1996, a multicontinent con-
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sortium, again led by Alan Bale, published their identifi-
cation of the same gene, and they were smart enough to 
get there without needing a lucky phone call (Hahn et al., 
1996).
The next lucky phone call was from Fred de Sauvage, 
at that time a young researcher and now vice president of 
Research Molecular Oncology at Genentech. His lab had 
cloned the human SMO gene, which encodes the protein 
that functions as the next step in the pathway, and togeth-
er we found activating mutations in this gene (Xie et al., 
1998), thus nailing the concept that it is elevated HH sig-
naling that underlies all BCCs. Matt Scott’s lab made a 
Gorlin mouse (i.e., Ptch1+/–) to study more fully the role of 
hedgehog (HH) signaling in development. He graciously 
gave it to us for studies of murine BCC carcinogenesis; we 
now have produced untold numbers of these furry beasts, 
all descended from one genetically engineered mouse, 
and they have been the linchpins of all our lab’s work for 
the past 1½ decades. 
But—except for enabling prenatal diagnosis—what 
was the utility of that discovery? At least theoretically, it 
opened the door to making a drug that might shut down 
the aberrant signaling pathway and thereby at least treat 
or, dare we hope, even cure BCCs. Scientifically, the way 
seemed clear, and Fred de Sauvage championed this proj-
ect at Genentech. Alas, the company’s leadership, like 
that at most pharmaceutical companies, decided that 
BCCs were so well treated surgically that it was not worth 
the investment—better to pursue medical needs that 
seemed more unmet. Fortunately, data published in 2003 
and 2004 suggested that enhanced HH signaling might 
be responsible for as many as 25% of all visceral can-
cers (e.g., Watkins et al., 2003; Berman et al., 2003), and 
after that Pharma became highly eager to develop an HH 
inhibitor. Genentech partnered and eventually absorbed 
the HH inhibitor program that had been undertaken with 
the leadership of Lee Rubin (now a Harvard professor of 
stem cell biology) at Curis using a high-throughput screen 
of small molecules. 
The first such to be tested in vivo was Curis 61414, 
which has strong anti-BCC efficacy when applied to 
mouse skin but failed completely when applied to human 
skin (Tang et al., 2011). Although the reason for this dis-
parity is not completely understood, at least in part it was 
because of the perhaps order-of-magnitude greater bar-
rier function in human compared with mouse skin and 
the drug's intrinsically stronger inhibitory effect on the 
murine than on the human molecular target. This failure 
encouraged Genentech to focus its efforts on develop-
ing an oral drug. The fruit of these efforts was vismodegib 
(Erivedge), which in 2012 became the first HH inhibitor 
to be approved by the US Food and Drug Administration 
(FDA) for marketing for treatment of “advanced BCCs,” 
an evolutionary term currently used to describe those 
BCCs for which surgery is at best a poor option. The good 
news is that it has remarkable antihuman BCC efficacy—
approximately half of the very rare metastatic BCCs and 
the unusual but less rare locally advanced BCCs respond 
significantly (Sekulic et al. 2012; Basset-Seguin et al., 
2015). Genentech entrusted us with funds and medication 
during their phase II development of the drug, unusually 
early for such entrustment, enabling us to prosecute an 
investigator-initiated, double-blind, placebo-controlled 
trial of vismodegib’s anti-BCC efficacy in patients with 
Gorlin syndrome. We found that Gorlin BCCs essentially 
all melt away, eventually completely, and no new BCCs 
develop while patients remain on the drug. While partici-
pating in our trials, no patient has required excision of 
a BCC (Tang et al., 2012). Unfortunately, vismodegib has 
systemic adverse effects that are class specific (hair loss 
that is likely due to the requirement for hedgehog signal-
ing in anagen, taste loss that is likely due to the require-
ment for hedgehog signaling for taste bud development, 
and muscle cramps due to uncertain mechanisms). 
These adverse effects have been seen with other clini-
cally studied hedgehog inhibitors, including sonidegib 
(Odomzo), the Novartis HH inhibitor that was approved 
by the FDA in July 2015 for sale in the US. Because of 
these side effects, many patients stop taking the drug, and 
when Gorlin patients stop taking the drug, BCCs that are 
histologically and clinically cured recur in the same site 
covering the same skin surface. Fortunately, when the 
drug is restarted, the tumors remain sensitive, and we 
have not seen any nonadvanced BCC develop resistance 
to vismodegib in nearly six years of study. Unfortunately, 
all publicly reported clinical trials of the efficacy of vis-
modegib and of the other small-molecule HH inhibitors 
versus other cancers (e.g., colorectal, pancreatic, and 
ovarian cancers) have had disappointing results—BCCs 
and the subset of medulloblastomas that are hedgehog 
driven may be the only human tumors for which the cur-
rent class of HH inhibitors has therapeutic efficacy. 
I draw several lessons from my participation in the 
identification of the molecular target, testing a topical 
preparation on mouse BCCs, and testing the oral drug on 
humans:
1. Hillary’s speech writers were right—it takes a village, 
and in this case several villages—some with village elders 
such as J.B. Howell and other dermatologists who began 
describing patients with what now is termed BCNS in the 
1950s; Robert Gorlin, who (like Columbus) was the “last” 
to describe the syndrome and therefore has the honor of 
having his name attached; Eric Wieschaus and Christiane 
Nüsslein-Volhard, the Nobel laureates who described 
the hedgehog signaling pathway in 1980; and hunter-
gatherers such as the near dozen labs that worked col-
laboratively and competitively in the 1980s and 1990s to 
identify the gene whose mutations cause BCNS. Success 
also requires one or more of the near completely sepa-
rate villages (such as Genentech or Novartis) that have the 
resources to fund the highly specialized armies of medici-
nal chemists, regulatory personnel, clinical trialists, and 
many others needed to move from concept and opportu-
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nity to supplying an effective drug to the shelves of phar-
macies around the world.
2. It takes a lot of money to feed and maintain even the 
last of these villages. The National Institutes of Health tra-
ditionally has supported the first villages. But these vil-
lages need enormous amounts of funds to develop new 
drugs—the estimates continue to climb from the hundreds 
of millions to more than a billion—and hence pharma-
ceutical companies need to invest in drugs that have at 
least a chance of returning large amounts of money.
3. Given that the former villages have produced and no 
doubt will continue to produce more targets whose “hit-
ting” could significantly ameliorate various diseases of 
the skin, how can the interest of the latter villages be 
piqued sufficiently to unleash the large amounts of capital 
needed to bring such a drug to market? That’s really the 
big question. Two types of answers come to mind.
i. In the case of melanoma, and increasingly for pso-
riasis, the market opportunity is perceived as being 
large enough to develop drugs whose first indica-
tion is dermatologic, although many would consid-
er melanoma once it has left the skin an oncologic 
rather than a dermatologic disease. Can we find 
more dermatologic markets (numbers of patients 
× possible profit per patient) that are large enough 
that their targeting would justify the large amounts 
of capital that would have to be spent to develop 
new drugs specifically for those targets? In the case 
of the healing of chronic wounds and of the safe 
amelioration of eczema, the answer clearly would 
be affirmative. Perhaps this also might be the case 
for several orphan disease drugs with primarily skin 
manifestations because orphan diseases, at least 
for the time being, can command high prices per 
patient treated, and their path to approval may be 
less costly. But for the great majority of conditions 
to be found in any dermatologic text, the answer 
clearly is negative.
ii. In the case of hedgehog inhibitors for BCCs, it 
seems highly unlikely that the monies ever would 
have been spent were it to have been known that 
BCCs, and only a small subset of them (“advanced” 
or metastatic), would be the only market for the 
new drugs. The BCC drug came along on the coat-
tails of anticipated indications for pancreatic, 
colorectal, and other cancers. This is a time-hon-
ored path for new dermatologic drugs (i.e., using 
a drug developed for some other indication for a 
skin problem)—consider aminopterin and metho-
trexate decades ago and etanercept and other 
tumor necrosis factor inhibitors more recently for 
psoriasis, brimonidine for a red face, and steroids 
for almost everything. Could we repurpose newer 
drugs (or even old standbys) developed and utilized 
for other ailments for skin problems? Presumably to 
do so we would need to think more seriously about 
identifying such drug–skin targets and to institute 
a more structured approach to the problem. One 
example comes from the hedgehog inhibitor field. 
An in vitro targeted assay by Philip Beachy, then at 
Hopkins, of a large number of FDA-approved drugs 
identified both in vitro and in vivo (at least in our 
Ptch1+/– mice) antihedgehog/anti-BCC activity of 
itraconazole unrelated to its antifungal activity (Kim 
et al., 2010, 2013). Investigation of its anti-HH effi-
cacy in humans, including its anti–prostate cancer 
efficacy, is under way. Its potency is considerably 
less than that of vismodegib and other “profession-
al” hedgehog inhibitors but if we did not have the 
latter, perhaps it could have served as an at least 
partially effective anti-BCC treatment. The regula-
tory and financial hurdles blocking repurposing of 
an old drug are far lower than are those blocking 
development of a new drug. Are there more such in 
vitro screens of already approved drugs that might 
unearth yet other, even more useful surprises?
4. I have been extraordinarily fortunate to have seen work 
that our lab has done actually lead to something useful 
for patients. How many people get to work on the identi-
fication of the molecular basis of a disease and then lead 
the clinical trial of the first drug to replace the function 
of the defective gene? What underlies that good fortune, 
beyond a very healthy dose of good luck? I could have 
skipped the Cleveland trip and not have read about RB; 
Matt could have called someone else; we could have 
worked on a disease for which the identification of the 
mutant gene did not lead so clearly to a drug. Indeed, our 
own findings of keratin gene mutations in epidermoly-
sis bullosa simplex have not enabled a therapy. Part of 
it clearly depends on my having been surrounded from 
the start by very good individuals. Because of the exam-
ple set by my family, I grew up expecting to become a 
clinical scholar in an era in which the phrase “balanced 
life” had not yet been coined and never felt that work 
was drudgery. And my lab at the San Francisco General 
Hospital for 35 years was adjacent to that of Y.W. Kan, a 
pioneer in applying molecular biology to clinical prob-
lems; he was kind enough to teach us the fundamentals 
of this then-arcane field. More broadly, being immersed 
even half-time in a vibrant research university gave me 
exposure to new ideas and the sense that if these guys 
could employ new approaches, maybe so could I. Part of 
it depended on having the freedom to travel. For many 
years I was not only a faithful attendee at the meetings 
of the Society for Investigative Dermatology but also the 
sole card-carrying dermatologist at the annual meeting 
of the American Society for Human Genetics. Because 
of this, in 1980 I was, along with Alain Hovnanian, one 
of the two persons on the planet who knew something 
about two particular fields of knowledge—family linkage 
analysis and Mendelian diseases of the skin. And part of it 
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was because I had both a clinical practice and a lab that 
allowed me to approach whatever problem I wanted so 
that I could fantasize about how wonderful it would be if 
someday I could go to some far off country and see on the 
druggist’s shelf a drug whose development I had touched, 
even peripherally. It happened, and the patients are even 
happier than I am. Now if only we can convert remission 
into cure!
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